At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 2, 2026 at 08:00 ET
Revolution Medicines reported positive Phase 1/2 data for zoldonrasib in RAS G12D metastatic pancreatic cancer at ESMO GI 2026. In previously untreated patients, zoldonrasib plus chemotherapy showed an 82% objective response rate (ORR) with mFFX and a 61% ORR with GnP. In previously treated patients, the zoldonrasib plus daraxonrasib doublet achieved a 50% ORR and 9.6-month median progression-free survival in second-line, supporting two Phase 3 trials (RASolute 305 ongoing, RASolute 309 planned).
- Zoldonrasib plus mFFX in first-line metastatic RAS G12D PDAC: 82% ORR, 96% DCR (n=41).
- Zoldonrasib plus GnP in first-line: 61% ORR, 90% DCR (n=40).
- Zoldonrasib plus daraxonrasib in second-line: 50% ORR, 97% DCR, median PFS 9.6 months (n=30).
- Third-line-plus doublet: 47% ORR, 90% DCR, median OS 10.5 months (n=30).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access